iLIVE Medication Study — iLIVEmed  

Palliative Care Clinical Trial

Official title: Towards Medication Optimisation in the Last Phase of Life: iLIVE Medication Study

Status Not yet recruiting

Clinical Trial Summary

The iLIVE medication study is a before-after study where medication optimisation of patients with an estimated life expectancy of six months is investigated. The investigators will include 400 patients in 3 countries. The primary outcome is an assessment of the quality of life of patients, four weeks after baseline assessment

Clinical Trial Description

Rationale: Patients in the last phase of life often use many medications until shortly before they die. This is partly inevitable, because these patients often experience multiple distressing symptoms. However, for a considerable number of medications currently often used at the end of life, the benefit is debatable, e.g. because they are aimed at the long-term prevention of illness. Objective: the primary objective is to examine whether the use of a clinical decision support system (CDSS-OPTIMED), a personalized medication advice to attending physicians of patients in the last phase of life, contributes to patients' quality of life. Main study endpoints: the primary outcome is an assessment of the quality of life of patients, four weeks after baseline assessment Potential risks and benefits associated with participation: the intervention in the medication study supports physicians in using available evidence and knowledge when prescribing or deprescribing medication for patients in the last phase of life. The intervention does not involve experimental treatment or medication. The investigators expect no other risks than known side effects of (stopping) medications. The investigators are aware that the study population concerns vulnerable people who may experience fluctuating symptoms and levels of suffering across their disease trajectory. The investigators acknowledge the risk of overburdening participants. If patients feel burdened by participating in the study, they are encouraged to indicate that. ;

Related Conditions & MeSH terms

• Palliative Care

• NCT number: NCT04717882
• Study type: Interventional
• Source: Erasmus Medical Center
• Contact: Eline Elsten, MD
• Phone: +316-51996165
• Email: e.e.c.m.elsten@erasmusmc.nl
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 15, 2021
• Completion date: January 15, 2024